Biotechnology

Thursday Jan 26, 2023 - 1:40 pm

InvestorNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Featured in New Article

MetAlert (OTC: MLRT), a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders, recently announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec LLC. Offering affordable, scalable location-awareness technology solutions, TrakTec made the news in a new Fairmont Post article that discusses its SafetyNet(R) service and others like it that are providing peace of mind…

Thursday Jan 26, 2023 - 11:30 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for…

Wednesday Jan 25, 2023 - 12:54 pm

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms

India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently…

Wednesday Jan 25, 2023 - 11:24 am

InvestorNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Its Next-Gen SmartSole in Sweden

MetAlert (OTC: MLRT) today announced the launch of its new 4G GPS SmartSole in Sweden through its distribution partner Posifon AB. The upgraded GPS SmartSole introduction will be an important part of the national service agreement Posifon recently secured with major municipalities across Sweden related to providing home care, personal tracking and security for seniors. Initial shipments of the GPS SmartSole will be distributed to…

Wednesday Jan 25, 2023 - 9:55 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) $4.1M Placements Supported by Aegis Capital Corp. as Exclusive Placement Agent

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, recently announced the closing of both a registered direct and a private placement; the placements totaled approximately $4.1 million. Aegis Capital Corp. acted as exclusive placement agent for those placements. In the wealth management and investment banking business since 1984, Aegis has built a reputation for offering corporate finance and strategic advisory…

Tuesday Jan 24, 2023 - 11:58 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival…

Tuesday Jan 24, 2023 - 11:33 am

InvestorNewsBreaks – MetAlert Inc. (MLRT) Approaching Inflection Point of Its Growth Curve

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, is launching a suite of wearable companion products to its innovative SmartSole shoe insole units. “The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The…

Tuesday Jan 24, 2023 - 10:46 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Senior Medical Tech Veteran as New President

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing…

Tuesday Jan 24, 2023 - 9:55 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Closes on $4.1M Direct, Private Placement Offerings

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin and sexual wellness, has closed on its previously announced registered direct offering and concurrent private placement. The offering includes the purchase and sale of 4,315,787 shares in a registered direct offering, with the concurrent private placement calling for JUPW to issue and sell a total of 8,631,574 warrants to the same investors. The warrants…

Monday Jan 23, 2023 - 12:00 pm

InvestorNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced availability of its redeemable digital coupons for shareholders of record to claim on Upstream’s trading app. Upon successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade with others globally on Upstream to bring new potential customers into the…

Monday Jan 23, 2023 - 11:42 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently…

Monday Jan 23, 2023 - 10:44 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg…

Friday Jan 20, 2023 - 12:26 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA…

Friday Jan 20, 2023 - 12:11 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently revealed positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. “Silo Pharma provided an update on the ongoing study as of Dec. 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21…

Friday Jan 20, 2023 - 10:56 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Correction Regarding $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, on Thursday announced its entry into a definitive agreement with investors in a registered direct offering, as well as details surrounding a concurrent private placement. The company issued an update to the initial release to correct the final share count and closing date. The registered direct offering is for the purchase and…

Thursday Jan 19, 2023 - 12:52 pm

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Growing Patent Portfolio Poised to Have Disruptive Effect on Multibillion Markets

HeartBeam (NASDAQ: BEAT), a cardiac technology company with a track record for innovation and cutting-edge technology, recently announced that it was granted a patent for its 12-lead electrocardiogram (“ECG”) smartwatch-based monitor designed to identify heart attacks and complex cardiac arrhythmias. “The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated…

Thursday Jan 19, 2023 - 10:54 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced its entry into a definitive agreement with investors for the purchase and sale of 4,315,786 shares in a registered direct offering. In a concurrent private placement, Jupiter Wellness also agreed to issue to the same investors a total of 8,631,572 warrants to purchase up to one share of common stock,…

Thursday Jan 19, 2023 - 10:00 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pharma’s recent submission of its clinical trial application for an upcoming phase a trial evaluating Lucid-MS. A candidate for treatment of multiple sclerosis…

Wednesday Jan 18, 2023 - 1:08 pm

InvestorNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Makes News in Finding Missing Woman

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, last week announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec, a location-awareness technology company. Expected to close on or before March 17, 2023, the acquisition will include TrakTec’s active paying subscriber base, police department contracts, commercial ready tracking products, and backend platform and mobile…

Wednesday Jan 18, 2023 - 10:06 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights…

Tuesday Jan 17, 2023 - 10:11 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Among First of Nasdaq Companies to Dual List on Upstream

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, last week became the second NASDAQ company to dual list on Upstream under the ticker symbol JUPW. Jupiter Wellness released a digital collectible NFT to commemorate the dual listing, which is available for all Upstream participants to claim with the code “JUPW.” “We are thrilled to be among the first companies to…

Friday Jan 13, 2023 - 12:58 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast,…

Friday Jan 13, 2023 - 11:55 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved the repurchase under a normal course issuer bid; the bid is comprised of up to 1,925,210 of HUGE subordinate class B voting shares over the…

Friday Jan 13, 2023 - 9:45 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) CEO Reports on Company Accomplishments, Outlook through Shareholder Letter

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, is in an ideal position to be “profitable” in 2023. That was the outlook reported in a shareholder letter released by JUPW CEO Brian John. The letter noted 2022 highlights, such as the company becoming the second U.S. equity to dual list on Upstream, a revolutionary trading app for digital securities and…

Thursday Jan 12, 2023 - 12:39 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian…

Thursday Jan 12, 2023 - 10:42 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) CEO Featured in Traders News Source Interview

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, was featured in a new C-level interview with Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies. Branislav Vajdic, PhD, CEO and founder of HeartBeam joined Traders News Source’s Toni Loudenbeck…

Thursday Jan 12, 2023 - 9:49 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people…

Wednesday Jan 11, 2023 - 12:04 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating…

Wednesday Jan 11, 2023 - 9:44 am

InvestorNewsBreaks — MetAlert Inc. (MLRT), TrakTec Sign Heads of Terms Agreement for Upcoming Acquisition

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, signed a Heads of Terms agreement with TrakTec outlining details about the previously announced acquisition. The agreement noted that MLRT would acquire the location-awareness technology company in a cash and stock deal worth $4.5 million. The agreement also notes that the acquisition should be closed on or before…

Tuesday Jan 10, 2023 - 1:41 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Featured on ‘Gametime with Sequire’

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in a recent interview with Sequire Spotlight. In the program, MetAlert’s CEO Patrick Bertagna joined Host Carmel Fisher to discuss the company’s business model and goals heading into the near future. “We’re a medical device/technologies company. We cater to a specific segment of the population…

Tuesday Jan 10, 2023 - 11:02 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate,…

Tuesday Jan 10, 2023 - 10:20 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in…

Monday Jan 09, 2023 - 12:20 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain…

Monday Jan 09, 2023 - 11:50 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such…

Monday Jan 09, 2023 - 10:03 am

InvestorNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker…

Monday Jan 09, 2023 - 9:55 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates…

Friday Jan 06, 2023 - 11:31 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the…

Friday Jan 06, 2023 - 9:56 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax’s NanoAb…

Thursday Jan 05, 2023 - 12:38 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Receives Key Patent from European Patent Office

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that the patent was issued covering the company’s flagship technology that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device. This patent…

Thursday Jan 05, 2023 - 12:20 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the Virtual Investor 2023 “Companies to Watch” event. Climaco’s presentation is scheduled to take place beginning at 10 a.m. ET on Wednesday, Jan. 18,…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions